High Court Won't Hear Novo Foreign Liability Case

Law360, New York (October 21, 2013, 2:20 PM EDT) -- The U.S. Supreme Court on Monday rejected Novo Nordisk A/S' request that the high court review an Oregon state court's decision to assert jurisdiction over the company in a suit alleging its hormone therapy drug Activella caused a case of breast cancer.

The denial is a setback for Novo Nordisk, which had argued that the Circuit Court of Multnomah County, Ore., in violation of the company's constitutional due process rights, had incorrectly held that it had personal jurisdiction over the Danish drugmaker under a "stream of commerce"...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.